medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2021, Number 2

<< Back

Medicina & Laboratorio 2021; 25 (2)

High risk human papillomavirus detection and genotyping by multiplex real time PCR (RT-PCR HR HPV)

Mesa-Arango JA, Tapia-Vela LJ, Loaiza-Díaz N, Echeverry-Chica J, Toro-Montoya AI

Language: Spanish
References: 10
Page: 547-550
PDF size: 49.05 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Toro-Montoya AI, Tapia-Vela LJ. Virus del papilomahumano (VPH) y cáncer. Med Lab 2021;25:467-483. https://doi.org/10.36384/01232576.431.

  2. Arbeláez-Vásquez A, Carreño C, Coñazos-Ramírez L, Castillo A. Implementación de lanueva guía práctica clínica para la deteccióny manejo de lesiones precancerosas de cuellouterino en mujeres de la ciudad de Cali,Colombia. Infectio 2020;24:20-26. https://doi.org/10.22354/in.v24i1.823.

  3. Lagheden C, Eklund C, Lamin H, Kleppe SN,Lei J, Elfström KM, et al. Nationwide comprehensivehuman papillomavirus (HPV) genotypingof invasive cervical cancer. Br J Cancer2018;118:1377-1381. https://doi.org/10.1038/s41416-018-0053-6.

  4. Gradíssimo A, Burk RD. Molecular tests potentiallyimproving HPV screening and genotypingfor cervical cancer prevention. Expert Rev MolDiagn 2017;17:379-391. https://doi.org/10.1080/14737159.2017.1293525.

  5. Groves IJ, Coleman N. Pathogenesis of humanpapillomavirus-associated mucosal disease.J Pathol 2015;235:527-538. https://doi.org/10.1002/path.4496.

  6. Leal SM, Jr., Gulley ML. Current and emergingmolecular tests for human papillomavirus-relatedneoplasia in the genomic era. J Mol Diagn2017;19:366-377. https://doi.org/10.1016/j.jmoldx.2017.01.006.

  7. Ministerio de Salud y Protección Social, InstitutoNacional de Cancerología-ESE. Guíade Práctica Clínica para la detección y manejode lesiones precancerosas de cuello uterino.Guía No. 44. Bogotá D.C: Ministerio de Saludy Protección Social; 2014. Acceso 15 demarzo de 2021. Disponible en https://www.cancer.gov.co/Gu%C3%ADas-y-Protocolos/Gu%C3%ADas-de-Practica-clinica/LPC-Guiaprofesionales.pdf.

  8. Hesselink AT, Sahli R, Berkhof J, SnijdersPJ, van der Salm ML, Agard D, et al. Clinicalvalidation of Anyplex™ II HPV HR detectionaccording to the guidelines for HPV test requirementsfor cervical cancer screening. J ClinVirol 2016;76:36-39. https://doi.org/10.1016/j.jcv.2016.01.009.

  9. Jung S, Lee B, Lee KN, Kim Y, Oh EJ. Clinicalvalidation of Anyplex II HPV HR detection testfor cervical cancer screening in Korea. ArchPathol Lab Med 2016;140:276-280. https://doi.org/10.5858/arpa.2015-0117-OA.

  10. Oštrbenk A, Xu L, Arbyn M, Poljak M. Clinicaland analytical evaluation of the Anyplex IIHPV HR detection assay within the VALGENT-3framework. J Clin Microbiol 2018;56:e01176.https://doi.org/10.1128/jcm.01176-18.




2020     |     www.medigraphic.com